![Elliott Levy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elliott Levy
Direttore/Membro del Consiglio presso
OMEA THER
Patrimonio netto: 3 907 $ in data 31/03/2024
Profilo
Elliott M.
Levy is the founder of Intrepid Alliance.
Current jobs include Independent Non-Executive Director at NuCana Plc since 2021, Independent Director at Omega Therapeutics, Inc. since 2021, Director at Kinaset Therapeutics, Inc., Venture Partner at 5AM Venture Management LLC since 2022, Senior Advisor at The Boston Consulting Group, and Media Contact at HeartFlow, Inc. Former jobs include Chairman at Transcelerate Biopharma, Inc. from 2017 to 2019, Independent Director at Editas Medicine, Inc. from 2023 to 2026, SVP-Strategy, Operations, Research & Development at Amgen, Inc. from 2020 to 2021, Senior Vice President & Head-Specialty Development at Bristol Myers Squibb Co. from 1997 to 2014, and Member-Renal Division at The Brigham & Women's Hospital, Inc. Education includes a doctorate from Yale School of Medicine conferred in 1987 and undergraduate studies at Yale College.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
NUCANA PLC 0,05% | 19/06/2026 | 15.026 ( 0,05% ) | 3 907 $ | 31/03/2024 |
| 17/06/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
Posizioni attive di Elliott Levy
| Società | Posizione | Inizio |
|---|---|---|
| OMEA THER | Direttore/Membro del Consiglio | 01/03/2021 |
| NUCANA PLC | Direttore/Membro del Consiglio | 01/11/2021 |
| HEARTFLOW, INC. | Public Communications Contact | - |
5AM Venture Management LLC
 5AM Venture Management LLC Investment ManagersFinance 5AM Ventures invests in companies located in the US with an investment size ranging from $20 to $30 million. The firm targets companies operating in the fields of life sciences. It provides financing for early stage and corporate spin-out capital requirements and also makes co-investments. | Investitore di Private Equity | 01/01/2022 |
The Boston Consulting Group | Consulente / Consigliere | - |
Kinaset Therapeutics, Inc.
 Kinaset Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops inhaled therapeutics for respiratory diseases | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Elliott Levy
| Società | Posizione | Fine |
|---|---|---|
| EDITAS MEDICINE, INC. | Direttore/Membro del Consiglio | 04/08/2026 |
| AMGEN INC. | Direttore Tecnico/Scientifico/R&S | 01/05/2021 |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Provides biopharmaceutical research services | Presidente | 01/09/2019 |
| ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Elliott Levy
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
98
Relazioni di 1° grado
13
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 13 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
HeartFlow, Inc.
 HeartFlow, Inc. Packaged SoftwareTechnology Services Develops and commercializes AI-powered cardiac imaging software | Technology Services |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services Provides health care services | Health Services |
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Ventures invests in companies located in the US with an investment size ranging from $20 to $30 million. The firm targets companies operating in the fields of life sciences. It provides financing for early stage and corporate spin-out capital requirements and also makes co-investments. | Finance |
NuCana Plc
 NuCana Plc BiotechnologyHealth Technology Develops and commercializes novel anti-cancer medicines | Health Technology |
Editas Medicine, Inc.
 Editas Medicine, Inc. BiotechnologyHealth Technology Manufactures gene editing medicines | Health Technology |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Provides biopharmaceutical research services | Health Technology |
Yale College
 Yale College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Boston Consulting Group | |
Omega Therapeutics, Inc.
 Omega Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for general and rare genetic diseases, immunology, inflammation, oncology and metabolic diseases | Health Technology |
Kinaset Therapeutics, Inc.
Kinaset Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops inhaled therapeutics for respiratory diseases | Health Technology |
